Wajdi Dbouk, MD
Family Medicine · Anderson, SCNPI 1023073764
Payments from drug & device makers
Across 517 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Johnson & Johnson$1K
- GSK$797
- Novartis$505
- Lilly USA, LLC$496
- Novo Nordisk$492
- plus $4K from 28 others
What the payments were for
- Food & beverage$7,979100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,047 |
| Johnson & Johnson | 71 | $1,026 |
| GSK | 54 | $797 |
| Novartis | 32 | $505 |
| Lilly USA, LLC | 28 | $496 |
| Novo Nordisk | 43 | $492 |
| Bayer | 37 | $429 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $392 |
| Amgen | 26 | $354 |
| Merck | 21 | $342 |
| Boehringer Ingelheim | 13 | $286 |
| AbbVie(2 entities) | 17 | $275 |
| Pfizer | 18 | $273 |
| Amarin Pharma, Inc. | 10 | $165 |
| Abbott | 7 | $131 |
| Kowa Pharmaceuticals America, Inc. | 9 | $127 |
| Sanofi-aventis U.S. LLC | 8 | $122 |
| VBI Vaccine (delaware) Inc. | 4 | $82 |
| Nevro Corp. | 3 | $80 |
| SK Life Science, Inc. | 4 | $72 |
| Astellas Pharma US Inc | 4 | $69 |
| Boston Scientific | 2 | $68 |
| Dexcom, Inc. | 4 | $59 |
| Phathom Pharmaceuticals, Inc. | 2 | $54 |
| Paratek Pharmaceuticals, Inc. | 2 | $40 |
| Nestle Healthcare Nutrition Inc. | 3 | $40 |
| Insmed, Inc. | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $17 |
| Viatris Specialty LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,992 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 145 | $133,510 |
| JardianceEmpagliflozin | 65 | $71,819 |
| RybelsusSemaglutide | 34 | $71,752 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $63,663 |
| EntrestoSacubitril/Valsartan | 44 | $52,682 |
| EliquisApixaban | 40 | $41,490 |
| XareltoRivaroxaban | 25 | $29,375 |
| OzempicSemaglutide | 21 | $28,018 |
| LinzessLinaclotide | 19 | $25,455 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $22,609 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $17,286 |
| MyrbetriqMirabegron | 12 | $12,160 |
| KerendiaFinerenone | 11 | $10,823 |
| Nebivolol Hcl | 153 | $9,832 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $8,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,047 | $157,942180 claims |
| Novo NordiskRybelsus, Ozempic | $492 | $99,77155 claims |
| Boehringer IngelheimJardiance | $286 | $71,81965 claims |
| GSKTrelegy Ellipta | $797 | $63,66352 claims |
| NovartisEntresto | $505 | $52,68244 claims |
| PfizerEliquis, Dilantin | $273 | $43,21552 claims |
| Johnson & JohnsonXarelto | $1,026 | $29,37525 claims |
| AbbVieLinzess | $275 | $25,45519 claims |
| Astellas Pharma US IncMyrbetriq | $69 | $12,16012 claims |
| BayerKerendia | $429 | $10,82311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Anderson
- Erin CookseyAnderson$1.2M
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.